This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lee, J. H.
Right arrow Articles by Lee, S. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, J. H.
Right arrow Articles by Lee, S. H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2005, p. 1600-1603, Vol. 49, No. 4
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.4.1600-1603.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Impact of Clarithromycin Resistance on Eradication of Helicobacter pylori in Infected Adults

Jong Hwa Lee,1,2 Ji-Hyun Shin,1 Im Hwan Roe,3 Seung Ghyu Sohn,2 Jung Hun Lee,2 Geun Ho Kang,2 Han-Ki Lee,2 Byeong Chul Jeong,2 and Sang Hee Lee2*

Research Center of Gastroenterology,1 Department of Gastroenterology, Dankook University College of Medicine, Cheonan, Choongnamdo,3 Department of Biological Sciences, Myongji University, Yongin, Kyunggido, Republic of Korea2

Received 22 October 2004/ Returned for modification 23 November 2004/ Accepted 8 December 2004

The outcome of Helicobacter pylori infection was analyzed in 114 dyspeptic patients treated with triple-drug therapy including clarithromycin. Clarithromycin resistance (in 20.2% of our isolates) was mainly caused by an A2142G mutation in the 23S rRNA gene of H. pylori. H. pylori eradication was obtained in all patients with clarithromycin-susceptible isolates but not in any patients with clarithromycin-resistant isolates (P = 0.0001). Therefore, it would be useful to conduct H. pylori antimicrobial susceptibility testing of the first gastric biopsy culture before choosing the first three drugs for therapy of infected patients.

* Corresponding author. Mailing address: Department of Biological Sciences, Myongji University, San 38-2 Namdong, Yongin, Kyunggido 449-728, Republic of Korea. Phone: 82-31-330-6195. Fax: 82-31-335-8249. E-mail: sangheelee{at}mju.ac.kr.

Antimicrobial Agents and Chemotherapy, April 2005, p. 1600-1603, Vol. 49, No. 4
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.4.1600-1603.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Kobayashi, I., Murakami, K., Kato, M., Kato, S., Azuma, T., Takahashi, S., Uemura, N., Katsuyama, T., Fukuda, Y., Haruma, K., Nasu, M., Fujioka, T. (2007). Changing Antimicrobial Susceptibility Epidemiology of Helicobacter pylori Strains in Japan between 2002 and 2005. J. Clin. Microbiol. 45: 4006-4010 [Abstract] [Full Text]  
  • Fritz, E. L., Slavik, T., Delport, W., Olivier, B., van der Merwe, S. W. (2006). Incidence of Helicobacter felis and the Effect of Coinfection with Helicobacter pylori on the Gastric Mucosa in the African Population.. J. Clin. Microbiol. 44: 1692-1696 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»